Artículo
Targeting DNA damage response kinases in cancer therapy
Fecha de publicación:
05/2020
Editorial:
Elsevier Science
Revista:
Mutation Research-fundamental And Molecular Mechanisms Of Mutagenesis
ISSN:
0027-5107
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Cancer cells die when their decimated DNA damage response (DDR) unsuccessfully handles DNA damage. This notion has been successfully exploited when targeting PARP (poly ADP-ribose polymerase) in homologous recombination-deficient cells. With the greater understanding of DDR achieved in the last decade, new cancer therapy targets within the DDR network have been identified. Intriguingly, many of the molecules that have advanced into clinical trials are inhibitors of DDR kinases. This special issue is devoted to discussing the mechanism of cell killing and the level of success that such inhibitors have reached in pre-clinical and clinical settings.
Palabras clave:
ATM
,
Aurora kinase
,
PLK1
,
AKT
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(IIBBA)
Articulos de INST.DE INVEST.BIOQUIMICAS DE BS.AS(I)
Articulos de INST.DE INVEST.BIOQUIMICAS DE BS.AS(I)
Citación
Gottifredi, Vanesa; Targeting DNA damage response kinases in cancer therapy; Elsevier Science; Mutation Research-fundamental And Molecular Mechanisms Of Mutagenesis; 821; 111725; 5-2020; 1-12
Compartir
Altmétricas